Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Nuclease-resistant synthetic ribozymes: developing a new class of therapeutics
Nassim Usman, Lawrence M. Blatt
Nassim Usman, Lawrence M. Blatt
Published November 15, 2000
Citation Information: J Clin Invest. 2000;106(10):1197-1202. https://doi.org/10.1172/JCI11631.
View: Text | PDF
Perspective

Nuclease-resistant synthetic ribozymes: developing a new class of therapeutics

  • Text
  • PDF
Abstract

Authors

Nassim Usman, Lawrence M. Blatt

×

Figure 2

Options: View larger image (or click on image) Download as PowerPoint
Inhibition of colorectal cancer metastases to the liver by ANGIOZYME. Th...
Inhibition of colorectal cancer metastases to the liver by ANGIOZYME. The number of metastases to the liver 41 days after intrasplenic inoculation of KM12L4a cells is shown. ANGIOZYME was administered by continuous s.c. infusion for 28 days starting on day 3 after inoculation. Details are described in ref. 12. AP < 0.05.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts